和元生物(688238) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥59,574,128.09, representing a year-on-year increase of 93.48%[4] - The net profit attributable to shareholders was -¥42,170,292.32, indicating a significant loss compared to the previous year[4] - The net cash flow from operating activities was -¥62,542,304.19, reflecting increased operational costs due to expanded scale[4] - Basic and diluted earnings per share were both -¥0.0658, showing a decline compared to the previous year[5] - The company's net loss for Q1 2024 was ¥86,384,292.08, compared to a loss of ¥44,213,999.76 in Q4 2023, indicating a worsening financial position[28] - The net profit for Q1 2024 was -42,298,770.28 RMB, compared to -31,806,061.95 RMB in Q1 2023, representing an increase in net loss of approximately 33.5%[31] - The total comprehensive income for Q1 2024 was -42,736,982.02 RMB, compared to -31,926,525.95 RMB in Q1 2023, indicating a decline of about 33.9%[32] - Basic and diluted earnings per share for Q1 2024 were both -0.0658 RMB, compared to -0.0495 RMB in Q1 2023, reflecting a worsening in earnings per share[32] Revenue Breakdown - The increase in operating revenue was primarily driven by growth in the cell and gene therapy CDMO business[10] - The revenue from cell gene therapy CRO business was RMB 17.96 million, an increase of 30.98% compared to the same period last year[20] - The revenue from cell gene therapy CDMO business reached RMB 38.21 million, showing a significant growth of 146.50% year-on-year[20] - The company achieved a total revenue of RMB 59.57 million in the reporting period, representing a year-on-year growth of 93.48%[20] - Total operating revenue for Q1 2024 reached ¥59,574,128.09, a significant increase of 93.6% compared to ¥30,791,377.00 in Q1 2023[30] Costs and Expenses - Total operating costs for Q1 2024 were ¥117,835,749.83, up from ¥64,195,944.08 in Q1 2023, reflecting a year-over-year increase of 83.7%[30] - Research and development expenses totaled ¥13,787,220.55, accounting for 23.14% of operating revenue, a decrease of 13.46 percentage points year-on-year[5][11] - Research and development expenses for Q1 2024 were ¥13,787,220.55, compared to ¥11,269,831.53 in Q1 2023, marking an increase of 22.4%[30] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,568,964,189.92, down 1.33% from the end of the previous year[5] - The company's total liabilities increased to ¥552,392,907.97 from ¥545,124,164.98, reflecting a rise of 1.5%[28] - Total assets as of March 31, 2024, amounted to ¥2,568,964,189.92, a slight decrease from ¥2,603,492,225.50 at the end of 2023[29] - The total current assets as of March 31, 2024, were 1,201,276,304.58 RMB, an increase from 1,117,716,144.41 RMB as of December 31, 2023, indicating growth in liquidity[37] Cash Flow - Cash flow from operating activities showed a net outflow of -62,542,304.19 RMB in Q1 2024, compared to -32,994,071.49 RMB in Q1 2023, indicating a significant increase in cash burn[35] - Cash and cash equivalents decreased to ¥566,941,878.98 as of March 31, 2024, down from ¥657,048,399.97 at the end of 2023, a decline of 13.7%[26] - The company reported a total cash inflow from financing activities of 60,000,000.00 RMB in Q1 2024, down from 140,205,000.00 RMB in Q1 2023, reflecting a decrease of approximately 57.3%[35] Strategic Developments - The company secured new orders exceeding RMB 80 million during the reporting period[20] - The company assisted clients in obtaining 4 IND approval filings in China and the U.S., including 1 from the FDA, bringing the total to 36 approvals[20] - The company and its subsidiaries added 2 new authorized invention patents and 1 utility model patent during the reporting period, totaling 25 invention patents and 16 utility model patents[21] - The company invested RMB 6 million in an industry investment fund, which was registered in January 2024[22] - The company established two wholly-owned subsidiaries in January and February 2024, each with a registered capital of RMB 500,000[21] Employee Engagement - The first employee stock ownership plan was announced, indicating a strategic move to enhance employee engagement and retention[24]